SCHEMBL5772884

SCHEMBL5772884

O=C(O)Cc1cccc(S(=O)(=O)N2CCN(c3ccc(F)cc3)CC2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.57
HPGD P15428 2/20 0.57
KDM4E B2RXH2 3/20 0.54
POLB P06746 2/20 0.54
PTPN7 P35236 2/20 0.54
PTPN11 Q06124 1/20 0.54
RAB9A P51151 2/20 0.53
MAPT P10636 5/20 0.52
PKM P14618 1/20 0.52
MEN1 O00255 3/20 0.52
KMT2A Q03164 3/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
HTT P42858 1/20 0.51
CYP3A4 P08684 1/20 0.51
CYP2C9 P11712 1/20 0.51
CYP2C19 P33261 1/20 0.51
USP2 O75604 1/20 0.51
HSD17B10 Q99714 1/20 0.51
LMNA P02545 1/20 0.50
NPC1 O15118 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6357532 0.90 HTT (0.58) ALDH1A1HPGDPOLBPTPN11PKM
SCHEMBL5776880 0.88 LMNA (0.59) ALDH1A1PTPN11MAPTKMT2ASMN1; SMN2
SCHEMBL5748241 0.88 HTT (0.63) ALDH1A1PTPN11MAPTMEN1KMT2A
SCHEMBL5749090 0.85 LMNA (0.60) ALDH1A1POLBPTPN11MAPTPKM
SCHEMBL6348350 0.85 HSD11B1 (0.59) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5746692 0.85 TNF (0.54) ALDH1A1POLBPTPN11MAPTMEN1
SCHEMBL5749330 0.85 THRB (0.58) ALDH1A1PTPN11MAPTMEN1KMT2A
SCHEMBL5774095 0.85 KDM4E (0.56) ALDH1A1KDM4ESMN1; SMN2HTT
SCHEMBL5475523 0.85 HTT (0.51) ALDH1A1MAPTMEN1KMT2ASMN1; SMN2
SCHEMBL5746218 0.84 ALDH1A1 (0.59) ALDH1A1RAB9AMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD ALDH1A1 883/4885HPGD 1108/4885KDM4E 3692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.